EAM Gale, SD Beattie, J Hu, V Koivisto, MH Tan - Diabetes Care, 2007 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—Eligible trials were selected from the global program
of an insulin manufacturer. Included were studies in which patients were seen on a single screening
visit, pharmaceutical therapy was not altered before randomization, and A1C was ... Cited by 5 - Related articles - BL Direct - All 8 versions
- ►easd.org [PDF] EAM Gale - Diabetologia, 2009 - Springer Drugs for health generate wealth, and wealth drives the diabetes roadshow. Without it, the subsidised
seasonal migrations to our big meetings would grind to a halt, and the KOLs (Key Opinion
Leaders, for the uninitiated) would all be driving a different brand of car. Given that the ... Cited by 1 - Related articles - All 3 versions
CC Quinn, AL Gruber-Baldini, M Shardell, K Weed, … - Contemporary Clinical …, 2009 - Elsevier Physician practices (n = 36) in 4 geographic areas are randomly assigned to 1 of 4 study
groups. The intervention is a diabetes communication system, using mobile phones and
patient/physician portals to allow patient-specific treatment and communication. All ... Related articles - All 18 versions
- ►nih.gov SGHA Swinnen, JH DeVries - Diabetologia, 2009 - Springer Abstract Aims/hypothesis The aim of the present study was to investigate whether predetermined
contact frequency with the study team and endpoint insulin dose are associated with study outcomes
in basal insulin initiation trials in type 2 diabetes. Methods A systematic Medline search ... Related articles - All 3 versions
NR Tripathy, S Basha, R Jain, S Shetty, A … - J Assoc Phys India, 2008 - japi.org INTRODUCTION Exenatide is a 39 – amino acid peptide approved for adjunctive treatment of
type 2 diabetes. It is an incretin mimetic agent that is consistent in activity with the actions of
glucagon–like peptide 1. Proposed mechanisms of action include enhanced glucose ... Cited by 2 - Related articles - View as HTML - All 4 versions
LA Kosmiski, RH Eckel - Clinical Research in Diabetes and Obesity: …, 1997 - books.google.com Dyslipidemia in Noninsulin-Dependent Diabetes Mellitus Lisa A. Kosmiski and Robert H. Eckel
Introduction Noninsulin dependent diabetes mellitus (NIDDM) is a common metabolic dis- order
familiar to most physicians. Its complications and associated conditions are numerous ... Cited by 2 - Related articles
[CITATION] Inhaled Technosphere Insulin: glucose elimination at the right time?[abstract 443-P …
JL Leahy - The American journal of the medical sciences, 2006 - journals.lww.com ABSTRACT: The majority of patients with type 2 diabe- tes mellitus (T2DM) eventually require
the addition of basal insulin to existing oral therapy to achieve the glycemic goals set forth by
the American Diabetes As- sociation (A1C, 7.0%). In many patients with T2DM, insulin is ... Cited by 2 - Related articles - BL Direct - All 6 versions
J Rosenstock, R Bergenstal, RA DeFronzo, IB … - Diabetes care, 2008 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—Patients (n = 126) were randomly assigned to 12 weeks
of therapy with Technosphere insulin or Technosphere powder after lifestyle education on
nutrition, exercise, and instructions on inhaler use. The primary efficacy outcome was ... Cited by 2 - Related articles - All 5 versions
MR Lankisch, KC Ferlinz, JL Leahy, WA … - Diabetes, obesity & …, 2008 - ncbi.nlm.nih.gov AIM: To investigate whether the addition of a single bolus of insulin glulisine (glulisine), administered
at either breakfast or main mealtime, in combination with basal insulin glargine (glargine) and
oral antidiabetic drugs (OADs), provides equivalent glycaemic control in patients with type ... Cited by 2 - Related articles
